Clinical trials
Metastatic Basal Cell Carcinoma clinical trials
Below are recruiting metastatic basal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 231 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04734730RecruitingPhase 2
Talazoparib plus hormone therapy for metastatic prostate cancer
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Duarte, CaliforniaAges 18 years+ - NCT05800223RecruitingPhase 3
Armatinib with or without brain radiation for EGFR lung cancer
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07847190RecruitingPhase 2
Adding paclitaxel to standard chemotherapy for tough testicular cancer
This trial tests if adding a drug called paclitaxel to the standard chemotherapy combination (BEP) can improve outcomes for people with aggressive testicular cancer. It is for those whose tumor markers did not drop as fast as expected after the first round of chemo.
MoscowAges 16 years+ - NCT07705243RecruitingPhase 3
Maintenance therapy for advanced nasopharyngeal cancer
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Guangzhou, GuangdongAges 18–75 - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT03370406RecruitingPhase 1
Test cream and injection treatment for skin squamous cell cancer
This early-phase study tests whether combining an injection into the skin lesion with a topical cream can treat squamous cell skin cancer. It may help shrink the cancer and improve control in people whose tumor is in the lower legs or feet.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06902389RecruitingPhase 1/Phase 2
Multi-target immune cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy (multi-target Hi-TCR-T cells) for people with advanced liver cancer that hasn't responded to earlier treatments. The therapy targets several markers on your cancer cells to try to attack the tumor more effectively.
Shanghai, Yangpu DistrictAges 18–75 - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT06517953RecruitingPhase 2
Testing two targeted pills for rare EGFR lung cancer
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Guangzhou, GuangdongAges 18 years+ - NCT04854213Recruiting
Study checks radiation effects in colon cancer lung-limited spread
This trial studies how targeted radiation (SBRT) affects cancer biology and immune cells in people with colon cancer that has spread only to a small number of lung nodules. Your tumor tissue will be analyzed to see what changes after treatment.
Naples, NAPOLIAges 18–80 - NCT07153887RecruitingPhase 2
Vebreltinib for advanced clear cell sarcoma
This trial tests the drug vebreltinib for people with advanced or spreading clear cell sarcoma. The goal is to see if it can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 12 years+ - NCT06841172RecruitingPhase 3
Radiation vs treatment switch for limited liver cancer growth
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
Jinan, ShandongAges 18–75 - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT07056556RecruitingPhase 1
Study of BL-M09D1 for advanced lung and other solid tumors
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+ - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75
Hear when a new Metastatic Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic basal cell carcinoma?
- Yes. Clin2 currently lists 231 recruiting metastatic basal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic basal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic basal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Basal Cell Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.